Logo image of AGIO

AGIOS PHARMACEUTICALS INC (AGIO) Stock Fundamental Analysis

USA - NASDAQ:AGIO - US00847X1046 - Common Stock

42.71 USD
+0.06 (+0.14%)
Last: 10/21/2025, 1:35:00 PM
Fundamental Rating

5

Taking everything into account, AGIO scores 5 out of 10 in our fundamental rating. AGIO was compared to 534 industry peers in the Biotechnology industry. AGIO has a great financial health rating, but its profitability evaluates not so good. AGIO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year AGIO has reported negative net income.
In the past year AGIO has reported a negative cash flow from operations.
In multiple years AGIO reported negative net income over the last 5 years.
In the past 5 years AGIO always reported negative operating cash flow.
AGIO Yearly Net Income VS EBIT VS OCF VS FCFAGIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

1.2 Ratios

With an excellent Return On Assets value of 44.19%, AGIO belongs to the best of the industry, outperforming 99.44% of the companies in the same industry.
AGIO has a better Return On Equity (47.47%) than 98.50% of its industry peers.
Industry RankSector Rank
ROA 44.19%
ROE 47.47%
ROIC N/A
ROA(3y)-5.26%
ROA(5y)11.49%
ROE(3y)-6.92%
ROE(5y)4.3%
ROIC(3y)N/A
ROIC(5y)N/A
AGIO Yearly ROA, ROE, ROICAGIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

The Profit Margin of AGIO (1590.42%) is better than 99.63% of its industry peers.
AGIO has a better Gross Margin (88.18%) than 89.70% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 1590.42%
GM 88.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AGIO Yearly Profit, Operating, Gross MarginsAGIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

More info and screens

9

2. Health

2.1 Basic Checks

AGIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGIO has been increased compared to 1 year ago.
Compared to 5 years ago, AGIO has less shares outstanding
AGIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AGIO Yearly Shares OutstandingAGIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
AGIO Yearly Total Debt VS Total AssetsAGIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

AGIO has an Altman-Z score of 14.06. This indicates that AGIO is financially healthy and has little risk of bankruptcy at the moment.
AGIO's Altman-Z score of 14.06 is amongst the best of the industry. AGIO outperforms 86.52% of its industry peers.
AGIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.06
ROIC/WACCN/A
WACC9.37%
AGIO Yearly LT Debt VS Equity VS FCFAGIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 14.48 indicates that AGIO has no problem at all paying its short term obligations.
With an excellent Current ratio value of 14.48, AGIO belongs to the best of the industry, outperforming 89.33% of the companies in the same industry.
A Quick Ratio of 14.04 indicates that AGIO has no problem at all paying its short term obligations.
AGIO's Quick ratio of 14.04 is amongst the best of the industry. AGIO outperforms 88.58% of its industry peers.
Industry RankSector Rank
Current Ratio 14.48
Quick Ratio 14.04
AGIO Yearly Current Assets VS Current LiabilitesAGIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for AGIO have decreased strongly by -12.86% in the last year.
Measured over the past years, AGIO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.03% on average per year.
AGIO shows a strong growth in Revenue. In the last year, the Revenue has grown by 30.56%.
EPS 1Y (TTM)-12.86%
EPS 3Y-24.03%
EPS 5YN/A
EPS Q2Q%-14.2%
Revenue 1Y (TTM)30.56%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%44.57%

3.2 Future

Based on estimates for the next years, AGIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.93% on average per year.
Based on estimates for the next years, AGIO will show a very strong growth in Revenue. The Revenue will grow by 92.49% on average per year.
EPS Next Y-8.09%
EPS Next 2Y-3.61%
EPS Next 3Y7.31%
EPS Next 5Y16.93%
Revenue Next Year26.07%
Revenue Next 2Y76.9%
Revenue Next 3Y94.64%
Revenue Next 5Y92.49%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
AGIO Yearly Revenue VS EstimatesAGIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
AGIO Yearly EPS VS EstimatesAGIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AGIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AGIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGIO Price Earnings VS Forward Price EarningsAGIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGIO Per share dataAGIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.61%
EPS Next 3Y7.31%

More info and screens

0

5. Dividend

5.1 Amount

AGIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AGIOS PHARMACEUTICALS INC

NASDAQ:AGIO (10/21/2025, 1:35:00 PM)

42.71

+0.06 (+0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners108.68%
Inst Owner Change0.1%
Ins Owners0.87%
Ins Owner Change0.86%
Market Cap2.48B
Analysts78.57
Price Target49.57 (16.06%)
Short Float %8.59%
Short Ratio5.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.06%
Min EPS beat(2)-4.68%
Max EPS beat(2)14.81%
EPS beat(4)2
Avg EPS beat(4)-71.89%
Min EPS beat(4)-314.16%
Max EPS beat(4)16.46%
EPS beat(8)4
Avg EPS beat(8)-34.24%
EPS beat(12)8
Avg EPS beat(12)-7.97%
EPS beat(16)11
Avg EPS beat(16)-5.1%
Revenue beat(2)1
Avg Revenue beat(2)8.78%
Min Revenue beat(2)-11.26%
Max Revenue beat(2)28.81%
Revenue beat(4)2
Avg Revenue beat(4)5.81%
Min Revenue beat(4)-11.26%
Max Revenue beat(4)28.81%
Revenue beat(8)2
Avg Revenue beat(8)-0.72%
Revenue beat(12)4
Avg Revenue beat(12)-3.31%
Revenue beat(16)5
Avg Revenue beat(16)-11.5%
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.85%
EPS NY rev (1m)-0.34%
EPS NY rev (3m)-2.45%
Revenue NQ rev (1m)-0.7%
Revenue NQ rev (3m)4.8%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)1.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 60.71
P/FCF N/A
P/OCF N/A
P/B 1.81
P/tB 1.81
EV/EBITDA N/A
EPS(TTM)-7.34
EYN/A
EPS(NY)-7.51
Fwd EYN/A
FCF(TTM)-7.04
FCFYN/A
OCF(TTM)-6.99
OCFYN/A
SpS0.7
BVpS23.57
TBVpS23.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 44.19%
ROE 47.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1590.42%
GM 88.18%
FCFM N/A
ROA(3y)-5.26%
ROA(5y)11.49%
ROE(3y)-6.92%
ROE(5y)4.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.67%
Cap/Sales 7.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.48
Quick Ratio 14.04
Altman-Z 14.06
F-Score4
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)33.97%
Cap/Depr(5y)62.68%
Cap/Sales(3y)14.2%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.86%
EPS 3Y-24.03%
EPS 5YN/A
EPS Q2Q%-14.2%
EPS Next Y-8.09%
EPS Next 2Y-3.61%
EPS Next 3Y7.31%
EPS Next 5Y16.93%
Revenue 1Y (TTM)30.56%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%44.57%
Revenue Next Year26.07%
Revenue Next 2Y76.9%
Revenue Next 3Y94.64%
Revenue Next 5Y92.49%
EBIT growth 1Y-13.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.55%
EBIT Next 3Y6.42%
EBIT Next 5YN/A
FCF growth 1Y-36.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.6%
OCF growth 3YN/A
OCF growth 5YN/A